Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 retinal gene therapy for choroideremia with AAV2-REP1 (timrepigene emparvovec)
2015-003958-41Phase 3Completed
- Sponsor
- Nightstar Therapeutics
- Start
- Mar 2016
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of timrepigene emparvovec in choroideremia (2 arms), sponsored by Nightstar Therapeutics. Primary endpoint: Best corrected visual acuity (BCVA) change from baseline. Started Mar 2016; status: completed.
02
Drugs
timrepigene emparvovec
03
Conditions
choroideremia
Beyond the preview
Go deeper on 2015-003958-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003958-41.